AVIX .0011-Releases--Three-Year-Financial-Model
AVIX Releases Three Year Financial Model For MyLottoClicks Software 06/05 09:30 AM
TORONTO--(BUSINESS WIRE)-- AVIX Technologies, Inc. (AVIX:$0.011,0$0.00,000.00%) announced today its three year financial model for MyLottoClicks software with projections prepared by Helpful Technologies, Inc.[color=red] These pro-formas anticipate gross revenues could exceed $72 million at the end of the three year forecast with capitalization exceeding $300 million. [/color]
After the launch of MyLottoClicks software, the Company expects to generate in gross revenue $8.1 million in year one, $26 million in year two and $ 38.3 million in year three.
Reno J. Calabrigo, President stated "We are very excited about the prospects for success that MyLottoClicks provides for the Company as we continually strive to maximize value to our shareholders."
About Helpful Technologies, Inc. www.helpfultechnologies.com
Helpful Technologies Inc. is a private developer of cutting-edge technological solutions for global markets. MyLottoClicks Software is a lottery numbers generator based on proprietary algorithm developed by Helpful Technologies Inc. in 2009.
About AVIX Technologies, Inc. (AVIX:$0.011,0$0.00,000.00%) www.avixt.com
AVIX is focused on identifying potential acquisitions and joint venture opportunities in various target markets that offer leading edge technology and services on a global scale.
Safe Harbor
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of AVIX Technologies, Inc. (AVIX:$0.011,0$0.00,000.00%) with members of its management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Source: AVIX Technologies, Inc. (AVIX:$0.011,0$0.00,000.00%)
Get more news on:SYMBOLS: AVIXNEWS TYPE: SECTORS: Energy, Oil, Gas and Consumable Fuels, Information Technology, Computers and Peripherals, Software
AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX AVIX
AVIX .0011-Releases--Three-Year-Financial-Model AVIX
Top 10 Most Recent News Articles
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
Webull Faces Class Action: Key Details for Investors
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early
Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...
Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion
Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...
Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading